首页> 外文期刊>Disease management and health outcomes >Impact of Antimicrobial Control Programs on Patient Outcomes Pharmacy Perspective
【24h】

Impact of Antimicrobial Control Programs on Patient Outcomes Pharmacy Perspective

机译:抗菌药物控制程序对患者结果的影响药房观点

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Antimicrobial control programs are now commonplace in institutional settings, with pharmacists taking acentral role in their inception and implementation. These programs often contain a variety of individual systems including formularies, restricted access, clinical pathways, antimicrobial management services, streamlining, intravenous to oral conversions and provider education. Economic concerns and the desire to limit antimicrobial resistance have driven a majority of these programs. Most antimicrobial controls have a potential to improve patient care through appropriate antimicrobial use and avoidance of adverse drug effects. However, there also exists a potential for impairing patient outcomes by dictating antimicrobial selection and use. The impact of these programs on patient clinical outcomes is not well documented. In studies where clinical outcomes were collected, most found no significant differences in resolution of infection, mortality, or the incidence of adverse drug reactions. However, no studies reported a significant negative impact on patient outcomes. Further research is needed to evaluate the clinical impact of antimicrobial control programs. It is imperative to combine clinical outcomes with the economic and resistance outcomes generated. Pharmacists must continue to be involved in antimicrobial control programs and should strive to include patient outcomes in all evaluations.
机译:如今,抗菌控制计划在机构环境中已司空见惯,药剂师在其创立和实施过程中起着中心作用。这些程序通常包含各种单独的系统,包括配方,限制进入,临床途径,抗菌药物管理服务,精简,静脉内到口服转化以及提供者教育。经济上的考虑和限制抗菌素耐药性的愿望推动了这些计划的大多数。大多数抗菌药物控制措施都有可能通过适当使用抗菌药物和避免药物不良反应来改善患者护理。但是,通过指示抗菌药物的选择和使用,也有可能损害患者的治疗效果。这些程序对患者临床结果的影响尚未得到充分记录。在收集临床结果的研究中,大多数发现感染,死亡率或药物不良反应的发生率没有显着差异。但是,没有研究报告对患者预后有重大负面影响。需要进一步的研究来评估抗菌控制程序的临床影响。必须将临床结果与产生的经济和耐药性结果结合起来。药剂师必须继续参与抗菌素控制计划,并应努力在所有评估中包括患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号